RU2017134519A - Терапевтические композиции и способы применения для лечения рака - Google Patents
Терапевтические композиции и способы применения для лечения рака Download PDFInfo
- Publication number
- RU2017134519A RU2017134519A RU2017134519A RU2017134519A RU2017134519A RU 2017134519 A RU2017134519 A RU 2017134519A RU 2017134519 A RU2017134519 A RU 2017134519A RU 2017134519 A RU2017134519 A RU 2017134519A RU 2017134519 A RU2017134519 A RU 2017134519A
- Authority
- RU
- Russia
- Prior art keywords
- cancer
- oncolytic virus
- virus
- paragraphs
- enzyme
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title claims 14
- 201000011510 cancer Diseases 0.000 title claims 10
- 238000000034 method Methods 0.000 title claims 8
- 239000000203 mixture Substances 0.000 title 1
- 230000001225 therapeutic effect Effects 0.000 title 1
- 244000309459 oncolytic virus Species 0.000 claims 21
- 108090000790 Enzymes Proteins 0.000 claims 6
- 102000004190 Enzymes Human genes 0.000 claims 6
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 241000700605 Viruses Species 0.000 claims 3
- 210000004027 cell Anatomy 0.000 claims 3
- 150000007523 nucleic acids Chemical class 0.000 claims 3
- 241000701161 unidentified adenovirus Species 0.000 claims 3
- 241000711975 Vesicular stomatitis virus Species 0.000 claims 2
- 208000035269 cancer or benign tumor Diseases 0.000 claims 2
- 208000032839 leukemia Diseases 0.000 claims 2
- 108020004707 nucleic acids Proteins 0.000 claims 2
- 102000039446 nucleic acids Human genes 0.000 claims 2
- 201000003076 Angiosarcoma Diseases 0.000 claims 1
- 206010003571 Astrocytoma Diseases 0.000 claims 1
- 241000711404 Avian avulavirus 1 Species 0.000 claims 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims 1
- 206010004146 Basal cell carcinoma Diseases 0.000 claims 1
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 201000009030 Carcinoma Diseases 0.000 claims 1
- 206010008342 Cervix carcinoma Diseases 0.000 claims 1
- 208000005243 Chondrosarcoma Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 108020004414 DNA Proteins 0.000 claims 1
- 206010058314 Dysplasia Diseases 0.000 claims 1
- 208000031637 Erythroblastic Acute Leukemia Diseases 0.000 claims 1
- 208000036566 Erythroleukaemia Diseases 0.000 claims 1
- 208000006168 Ewing Sarcoma Diseases 0.000 claims 1
- 201000008808 Fibrosarcoma Diseases 0.000 claims 1
- 102000030902 Galactosyltransferase Human genes 0.000 claims 1
- 108060003306 Galactosyltransferase Proteins 0.000 claims 1
- 206010018338 Glioma Diseases 0.000 claims 1
- 208000001258 Hemangiosarcoma Diseases 0.000 claims 1
- 208000017604 Hodgkin disease Diseases 0.000 claims 1
- 208000021519 Hodgkin lymphoma Diseases 0.000 claims 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 241000712079 Measles morbillivirus Species 0.000 claims 1
- 206010029260 Neuroblastoma Diseases 0.000 claims 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 1
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 1
- 201000010133 Oligodendroglioma Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 241000125945 Protoparvovirus Species 0.000 claims 1
- 208000006265 Renal cell carcinoma Diseases 0.000 claims 1
- 241000702263 Reovirus sp. Species 0.000 claims 1
- 201000000582 Retinoblastoma Diseases 0.000 claims 1
- 206010041067 Small cell lung cancer Diseases 0.000 claims 1
- 208000024313 Testicular Neoplasms Diseases 0.000 claims 1
- 102000004357 Transferases Human genes 0.000 claims 1
- 108090000992 Transferases Proteins 0.000 claims 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 1
- 208000002495 Uterine Neoplasms Diseases 0.000 claims 1
- 241000700618 Vaccinia virus Species 0.000 claims 1
- 108700005077 Viral Genes Proteins 0.000 claims 1
- 208000008383 Wilms tumor Diseases 0.000 claims 1
- 208000021841 acute erythroid leukemia Diseases 0.000 claims 1
- 208000009956 adenocarcinoma Diseases 0.000 claims 1
- 230000002567 autonomic effect Effects 0.000 claims 1
- 210000000170 cell membrane Anatomy 0.000 claims 1
- 201000010881 cervical cancer Diseases 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims 1
- 238000010367 cloning Methods 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 230000009089 cytolysis Effects 0.000 claims 1
- 238000012217 deletion Methods 0.000 claims 1
- 230000037430 deletion Effects 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 210000004907 gland Anatomy 0.000 claims 1
- 230000013595 glycosylation Effects 0.000 claims 1
- 238000006206 glycosylation reaction Methods 0.000 claims 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims 1
- 125000000625 hexosyl group Chemical group 0.000 claims 1
- 206010020718 hyperplasia Diseases 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 238000007918 intramuscular administration Methods 0.000 claims 1
- 238000007912 intraperitoneal administration Methods 0.000 claims 1
- 230000002601 intratumoral effect Effects 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 206010024627 liposarcoma Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 239000008267 milk Substances 0.000 claims 1
- 210000004080 milk Anatomy 0.000 claims 1
- 235000013336 milk Nutrition 0.000 claims 1
- 208000001611 myxosarcoma Diseases 0.000 claims 1
- 208000025189 neoplasm of testis Diseases 0.000 claims 1
- 201000008026 nephroblastoma Diseases 0.000 claims 1
- 201000008968 osteosarcoma Diseases 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 230000010076 replication Effects 0.000 claims 1
- 230000003362 replicative effect Effects 0.000 claims 1
- 208000000587 small cell lung carcinoma Diseases 0.000 claims 1
- 206010041823 squamous cell carcinoma Diseases 0.000 claims 1
- 238000007920 subcutaneous administration Methods 0.000 claims 1
- 201000003120 testicular cancer Diseases 0.000 claims 1
- 239000000439 tumor marker Substances 0.000 claims 1
- 241001529453 unidentified herpesvirus Species 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
- 206010046766 uterine cancer Diseases 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
- A61K35/761—Adenovirus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
- A61K35/768—Oncolytic viruses not provided for in groups A61K35/761 - A61K35/766
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/45—Transferases (2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0031—Rectum, anus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/1048—Glycosyltransferases (2.4)
- C12N9/1051—Hexosyltransferases (2.4.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y204/00—Glycosyltransferases (2.4)
- C12Y204/01—Hexosyltransferases (2.4.1)
- C12Y204/01087—N-Acetyllactosaminide 3-alpha-galactosyltransferase (2.4.1.87), i.e. alpha-1,3-galactosyltransferase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10332—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10371—Demonstrated in vivo effect
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
- C12N2710/16632—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
- C12N2710/16641—Use of virus, viral particle or viral elements as a vector
- C12N2710/16643—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
- C12N2710/16671—Demonstrated in vivo effect
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y204/00—Glycosyltransferases (2.4)
- C12Y204/01—Hexosyltransferases (2.4.1)
- C12Y204/01057—Phosphatidylinositol alpha-mannosyltransferase (2.4.1.57)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Mycology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Dermatology (AREA)
- Gynecology & Obstetrics (AREA)
- Reproductive Health (AREA)
- Otolaryngology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Claims (23)
1. Онколитический вирус, содержащий нуклеиновую кислоту, кодирующую фермент гексозилтрансферазу.
2. Онколитический вирус по п.1, в котором фермент представляет собой фермент галактозилтрансферазу.
3. Онколитический вирус по п.1 или 2, в котором фермент представляет собой фермент альфа 1,3-галактозилтрансферазу.
4. Онколитический вирус по любому из пп. 1-3, который содержит рекомбинантный связывающий домен, специфичный для маркера стволовой опухолевой клетки.
5. Онколитический вирус по любому из пп. 1-4, который имеет ограниченную репликацию.
6. Онколитический вирус по любому из пп. 1-5, который представляет собой РНК- или ДНК-вирус человеческого или нечеловеческого происхождения, такой как аденовирус, герпесвирус, вирус коровьей оспы, вирус кори, вирус болезни Ньюкасла, автономные парвовирусы, вирус везикулярного стоматита (VSV) или реовирус.
7. Онколитический вирус по п.6, который представляет собой аденовирус.
8. Онколитический вирус по п.7, который представляет собой условно реплицирующийся аденовирус (CRAd).
9. Онколитический вирус по п.8, который представляет собой Ad5/3 химерный вирус.
10. Онколитический вирус по п.9, в котором Ad5/3 химерный вирус дополнительно содержит делецию 24 пар оснований (Δ24) в константной области 2 (CR2) вирусного гена немедленного раннего ответа (E1a) (Ad5/3-Δ24 CRAd).
11. Онколитический вирус по любому из пп. 1-10, который содержит последовательность нуклеиновых кислот, кодирующую альфа 1,3-галактозилтрансферазу.
12. Онколитический вирус по п.11, который представляет собой Ad5/3-Δ24-αGT CRAd (CRAd-αGT).
13. Фармацевтическая композиция, содержащая онколитический вирус по любому из пп. 1-12 в комбинации с фармацевтически приемлемым носителем.
14. Фармацевтическая композиция по п.13, которая составлена для внутривенного, внутримышечного, интраперитонеального, интратуморального, подкожного, перорального, ректального, интравагинального, интраназального, чресслизистого или трансдермального введения.
15. Способ лечения индивида с новообразованием, который включает стадии i) экспрессии эндогенного фермента, доставляемого онколитическим вирусом по любому из пп. 1-12 по меньшей мере в одну раковую клетку для модифицирования гликозилирования клеточной мембраны; и
ii) индуцирования лизиса по меньшей мере одной раковой клетки, возникающего в результате введения онколитического вируса.
16. Способ по п.15, в котором онколитический вирус вводят в эффективном количестве для инфицирования по меньшей мере одной раковой клетки индивида.
17. Способ по п.15 или 16, который направлен на лечение индивида с раком или индивида с опухолью.
18. Способ лечения рака, включающий введение терапевтически эффективного количества онколитического вируса по любому из пп. 1-12 пациенту, страдающему раком или имеющему новообразование или опухоль, нуждающемуся в лечении.
19. Онколитический вирус по любому из пп. 1-12 или фармацевтическая композиция по п.13 или 14 для применения в лечении рака.
20. Способ по любому из пп. 15-18 или онколитический вирус или фармацевтическая композиция по п.19, в котором рак выбран из лейкоза (например, миелобластного, промиелоцитарного, миеломоноцитарного, моноцитарного, эритролейкоза, хронического миелоцитарного (гранулоцитарного) лейкоза, и хронического лимфоцитарного лейкоза), лимфомы (например, ходжкинской лимфомы и неходжкинской лимфомы), фибросаркомы, миксосаркомы, липосаркомы, хондросаркомы, остеогенной саркомы, ангиосаркомы, эндотелиосаркомы, саркомы Юинга, рака ободочной кишки, рака поджелудочной железы, рака молочной железы, рака яичников, рака простаты, плоскоклеточного рака, базальноклеточного рака, аденокарциномы, почечно-клеточного рака, гепатомы, опухоли Вильмса, рака шейки матки, рака матки, опухоли яичка, рака легкого, мелкоклеточного рака легкого, рака мочевого пузыря, эпителиального рака, глиомы, астроцитомы, олигодендроглиомы, меланомы, нейробластомы, ретинобластомы, дисплазии и гиперплазии.
21. Способ получения онколитического вируса по любому из пп. 1-12, который включает стадию включения нуклеиновой кислоты, кодирующей фермент гексозилтрансферазу, в геном указанного онколитического вируса.
22. Способ по п.21, в котором указанная стадия включения включает клонирование.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1505860.5 | 2015-04-07 | ||
| GBGB1505860.5A GB201505860D0 (en) | 2015-04-07 | 2015-04-07 | Therapeutic compositions and methods of use for treating cancer |
| PCT/GB2016/050973 WO2016162675A1 (en) | 2015-04-07 | 2016-04-07 | Therapeutic compositions and methods of use for treating cancer |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| RU2017134519A true RU2017134519A (ru) | 2019-04-04 |
| RU2017134519A3 RU2017134519A3 (ru) | 2019-10-10 |
| RU2720984C2 RU2720984C2 (ru) | 2020-05-15 |
Family
ID=53190234
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2017134519A RU2720984C2 (ru) | 2015-04-07 | 2016-04-07 | Терапевтические композиции и способы применения для лечения рака |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US20180104288A1 (ru) |
| EP (1) | EP3280798B1 (ru) |
| JP (2) | JP2018512150A (ru) |
| KR (1) | KR102544032B1 (ru) |
| CN (1) | CN107787364A (ru) |
| BR (1) | BR112017021700A2 (ru) |
| CA (1) | CA2981925A1 (ru) |
| ES (1) | ES2743952T3 (ru) |
| GB (1) | GB201505860D0 (ru) |
| HK (1) | HK1251009B (ru) |
| IL (1) | IL254842B (ru) |
| MX (1) | MX2017012867A (ru) |
| RU (1) | RU2720984C2 (ru) |
| WO (1) | WO2016162675A1 (ru) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2971008B1 (en) | 2013-03-14 | 2018-07-25 | Salk Institute for Biological Studies | Oncolytic adenovirus compositions |
| JP7015551B2 (ja) | 2016-02-23 | 2022-02-15 | ソーク インスティテュート フォー バイオロジカル スタディーズ | ウイルス動態への影響を最小限にするための治療用アデノウイルスにおける外因性遺伝子発現 |
| JP7054527B2 (ja) | 2016-02-23 | 2022-04-14 | ソーク インスティテュート フォー バイオロジカル スタディーズ | アデノウイルスの複製動態を測定するための高スループットアッセイ |
| CA3045892A1 (en) | 2016-12-12 | 2018-06-21 | Salk Institute For Biological Studies | Tumor-targeting synthetic adenoviruses and uses thereof |
| CN110856724B (zh) * | 2018-08-24 | 2022-05-27 | 杭州康万达医药科技有限公司 | 包含核酸及car修饰的免疫细胞的治疗剂及其应用 |
| JPWO2020230838A1 (ru) * | 2019-05-14 | 2020-11-19 | ||
| CN115103905A (zh) * | 2020-01-10 | 2022-09-23 | 香港大学 | 表达α-1,3-半乳糖基转移酶的重组病毒及其用途 |
| CN112941039A (zh) * | 2021-02-01 | 2021-06-11 | 南京大学 | 一种新型类囊泡溶瘤病毒及其在制备抗肿瘤药物上的应用 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9615794D0 (en) | 1996-07-26 | 1996-09-04 | Medical Res Council | Mutant herpes simplex virus strains and uses thereof |
| US5998174A (en) | 1997-05-12 | 1999-12-07 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Multigene vectors |
| GB9810904D0 (en) | 1998-05-20 | 1998-07-22 | Univ London | Mutant herpes simplex viruses and uses thereof |
| DE60107203T3 (de) | 2000-01-21 | 2009-07-23 | Biovex Ltd. | Herpes-virusstämme für die gentherapie |
| US7338932B2 (en) * | 2000-05-11 | 2008-03-04 | Glycozym Aps | Methods of modulating functions of polypeptide GalNAc-transferases and of screening test substances to find agents herefor, pharmaceutical compositions comprising such agents and the use of such agents for preparing medicaments |
| US6713055B2 (en) | 2000-11-27 | 2004-03-30 | Geron Corporation | Glycosyltransferase vectors for treating cancer |
| US20030099616A1 (en) * | 2001-07-25 | 2003-05-29 | Irving John M. | Dual specificity tumor killing vectors driven by the telomerase promoter |
| DE60331933D1 (de) * | 2002-10-09 | 2010-05-12 | Central Iowa Healthy System | Benutzung von alpha (1,3) -galactosyltransferase exprimierenden allogenen tumorzellen zur impfung gegen tumoren |
| US20050201993A1 (en) * | 2002-10-09 | 2005-09-15 | Link Charles J.Jr. | Antitumor vaccination using allogeneic tumor cells expressing alpha (1,3)-galactosyltransferase |
| EA013615B1 (ru) * | 2004-11-12 | 2010-06-30 | Байер Шеринг Фарма Акциенгезельшафт | Рекомбинантный онколитический парамиксовирус и его применение |
| US7820628B2 (en) | 2005-02-22 | 2010-10-26 | University Of Massachusetts Medical School | Tumor lesion regression and conversion in situ into autologous tumor vaccines by compositions that result in anti-Gal antibody binding |
| EP2085092A1 (en) * | 2008-01-29 | 2009-08-05 | Bayer Schering Pharma Aktiengesellschaft | Attenuated oncolytic paramyxoviruses encoding avian cytokines |
| ES2385251B1 (es) * | 2009-05-06 | 2013-05-06 | Fundació Privada Institut D'investigació Biomèdica De Bellvitge | Adenovirus oncolíticos para el tratamiento del cáncer. |
| CA2836299A1 (en) * | 2011-04-15 | 2012-10-18 | Genelux Corporation | Clonal strains of attenuated vaccinia viruses and methods of use thereof |
| EP2929024B1 (en) * | 2012-12-07 | 2019-05-29 | North Carolina State University | Beta-hexosyl-transferases and uses thereof |
| CN105779397B (zh) * | 2014-12-22 | 2019-07-19 | 彭霞 | 溶瘤异源重组新城疫病毒及其制备方法与应用 |
-
2015
- 2015-04-07 GB GBGB1505860.5A patent/GB201505860D0/en not_active Ceased
-
2016
- 2016-04-07 ES ES16716896T patent/ES2743952T3/es active Active
- 2016-04-07 CA CA2981925A patent/CA2981925A1/en active Pending
- 2016-04-07 RU RU2017134519A patent/RU2720984C2/ru active
- 2016-04-07 MX MX2017012867A patent/MX2017012867A/es active IP Right Grant
- 2016-04-07 BR BR112017021700-7A patent/BR112017021700A2/pt not_active Application Discontinuation
- 2016-04-07 JP JP2017552992A patent/JP2018512150A/ja active Pending
- 2016-04-07 KR KR1020177027601A patent/KR102544032B1/ko active IP Right Grant
- 2016-04-07 CN CN201680020049.0A patent/CN107787364A/zh active Pending
- 2016-04-07 US US15/564,774 patent/US20180104288A1/en not_active Abandoned
- 2016-04-07 WO PCT/GB2016/050973 patent/WO2016162675A1/en active Application Filing
- 2016-04-07 EP EP16716896.2A patent/EP3280798B1/en active Active
-
2017
- 2017-10-02 IL IL254842A patent/IL254842B/en unknown
-
2018
- 2018-08-10 HK HK18110254.0A patent/HK1251009B/zh unknown
-
2019
- 2019-11-27 US US16/698,682 patent/US12023362B2/en active Active
-
2020
- 2020-12-02 JP JP2020199987A patent/JP7066812B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US12023362B2 (en) | 2024-07-02 |
| US20180104288A1 (en) | 2018-04-19 |
| HK1251009B (zh) | 2020-06-26 |
| BR112017021700A2 (pt) | 2018-07-24 |
| KR20180015113A (ko) | 2018-02-12 |
| RU2720984C2 (ru) | 2020-05-15 |
| CN107787364A (zh) | 2018-03-09 |
| CA2981925A1 (en) | 2016-10-13 |
| JP2021045152A (ja) | 2021-03-25 |
| RU2017134519A3 (ru) | 2019-10-10 |
| JP2018512150A (ja) | 2018-05-17 |
| IL254842A0 (en) | 2017-12-31 |
| ES2743952T3 (es) | 2020-02-21 |
| KR102544032B1 (ko) | 2023-06-14 |
| GB201505860D0 (en) | 2015-05-20 |
| JP7066812B2 (ja) | 2022-05-13 |
| IL254842B (en) | 2022-01-01 |
| US20200155626A1 (en) | 2020-05-21 |
| WO2016162675A1 (en) | 2016-10-13 |
| MX2017012867A (es) | 2018-05-11 |
| EP3280798A1 (en) | 2018-02-14 |
| EP3280798B1 (en) | 2019-06-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2017134519A (ru) | Терапевтические композиции и способы применения для лечения рака | |
| JP2018512150A5 (ru) | ||
| Mondal et al. | Recent advances of oncolytic virus in cancer therapy | |
| JPWO2017209053A1 (ja) | 新規な遺伝子組換えワクシニアウイルス | |
| US20170340687A1 (en) | Novel genetically engineered vaccinia viruses | |
| US10435672B2 (en) | Genetically stable oncolytic RNA virus, method of manufacturing and use thereof | |
| JP2017514483A5 (ru) | ||
| RU2016146664A (ru) | Аденовирус, содержащий альбумин-связывающий участок | |
| Jebar et al. | Progress in clinical oncolytic virus-based therapy for hepatocellular carcinoma | |
| AU2017299983B2 (en) | Recombinant vaccinia virus and use thereof | |
| Deng et al. | Oncolytic and immunologic cancer therapy with GM-CSF-armed vaccinia virus of Tian Tan strain Guang9 | |
| JP2016512230A5 (ru) | ||
| Sánchez et al. | Oncolytic viruses for canine cancer treatment | |
| Badrinath et al. | Viruses as nanomedicine for cancer | |
| RU2020124404A (ru) | Векторы на основе модифицированного вируса осповакцины | |
| KR20190097240A (ko) | 종양용해성 바이러스 및 치료 분자 | |
| Li et al. | Antitumor efficacy of a recombinant adenovirus encoding endostatin combined with an E1B55KD-deficient adenovirus in gastric cancer cells | |
| Gao et al. | Gene therapy targeting hepatocellular carcinoma by a dual-regulated oncolytic adenovirus harboring the focal adhesion kinase shRNA | |
| Lopez et al. | Tumor associated stromal cells play a critical role on the outcome of the oncolytic efficacy of conditionally replicative adenoviruses | |
| JP2004033186A (ja) | 腫瘍細胞において選択的に増殖する腫瘍融解ウイルス | |
| Li et al. | Preclinical and clinical trials of oncolytic vaccinia virus in cancer immunotherapy: a comprehensive review | |
| BR112022006926A2 (pt) | Vetor de vírus oncolítico que codifica o polipeptídeo variante de interleucina 2 (vil-2) | |
| MX2022013462A (es) | Variantes, formulaciones y metodos adeno-asociados para suministro pulmonar. | |
| Lettieri et al. | Progress of oncolytic viruses in sarcomas | |
| Liu et al. | Oncolytic vaccinia virotherapy for endometrial cancer |